EUVIMEDEUVIMED entdecken
Crossref

Utility of Pharmacologic Conversion of Persistent Atrial Fibrillation by Amiodarone as a Predictor of Outcome After Pulmonary Vein Isolation

Dóra Krányák iD, Adél Novák, Noémi Pataky, László Sághy, Máté Vámos, Tamás Szili-Török, Róbert Pap iD, Other Members of the Szeged Electrophysiology Study Group

Journal of Cardiovascular Electrophysiology · 2026

DOI: 10.1111/jce.70155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Dóra Krányák und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cardiology Center, Division of Electrophysiology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Amiodarone, Atrial Fibrillation, Pulmonary Veins, Anti-Arrhythmia Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Restoration and maintenance of sinus rhythm (SR) before pulmonary vein isolation (PVI) by antiarrhythmic drug (AAD) therapy can lead to a better outcome in persistent atrial fibrillation (AF). It is unknown, however if pharmacologic conversion by amiodarone loading itself, compared to the need for additional electrical cardioversion (ECV), predicts a better outcome of PVI. Furthermore, it remains controversial whether subsequent AF episodes occurring while on amiodarone before PVI, have any predictive value. Our aim was to assess whether amiodarone response before the procedure shows predictive value in patients with persistent AF undergoing PVI. Methods and Results We retrospectively collected data from consecutive patients with persistent AF who underwent PVI between 2013 and 2023, and who received temporary amiodarone therapy, with or without ECV to restore and maintain sinus rhythm before the intervention. A total of 353 patients (30% female, mean age: 63.76 ± 9.27 years) were included. Conversion to sinus rhythm was achieved solely by amiodarone therapy (AmioConv) in 96 patients (27%), while 257 patients (73%) required additional ECV as well. There were no differences between the two groups in terms of comorbidities, CHADS‐VASc score (2.46 ± 1.43 vs. 2.26 ± 1.48, p = 0.27), or echocardiographic parameters, but the AmioConv group had a shorter history of AF (2.22 ± 2.96 years vs. 3.74 ± 4.64 years, p < 0.01). During a mean follow‐up of 3.48 ± 2.32 years after PVI, patients in the AmioConv group less frequently experienced AF recurrences (41% vs. 56%, p = 0.016) and had significantly longer mean recurrence‐free survival (5.21 ± 0.54 vs. 3.6 ± 0.35 years, p < 0.01), compared to the ECV group. The lack of pharmacologic conversion by amiodarone therapy (need for ECV) was found to be the only independent predictor of post PVI recurrences (adjusted HR 1.86, 95% CI 1.21–2.85, p < 0.01). On the contrary, breakthrough episodes of AF during amiodarone therapy, before ablation, were not predictive (adjusted HR 0.87, 95% CI 0.57–1.32, p = 0.51).

Conclusion

In patients with persistent atrial fibrillation the outcome after PVI is predicted by pharmacologic conversion during amiodarone loading, but not the reoccurrence of the arrhythmia during continued pre‐ablation AAD therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneAtrial FibrillationPulmonary VeinsAnti-Arrhythmia AgentsCatheter AblationHeart RateHumansFemaleMaleMiddle AgedRetrospective StudiesAgedRecurrenceTime FactorsTreatment OutcomeAction PotentialsRisk FactorsElectric Countershock

Stichwörter der Autor:innen

amiodaronecardioversioncatheter ablationpersistent atrial fibrillationpulmonary vein isolation

Substanzen

AmiodaroneAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Cardiology Center, Division of Electrophysiology, University of Szeged, Szeged, Hungary.

ORCID-Profile: Dóra Krányák, Róbert Pap

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Krányák, D., Novák, A., Pataky, N., Sághy, L., Vámos, M., Szili-Török, T., Pap, R., & Other Members of the Szeged Electrophysiology Study Group (2026). Utility of Pharmacologic Conversion of Persistent Atrial Fibrillation by Amiodarone as a Predictor of Outcome After Pulmonary Vein Isolation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70155

Vancouver

Krányák D, Novák A, Pataky N, Sághy L, Vámos M, Szili-Török T, et al. Utility of Pharmacologic Conversion of Persistent Atrial Fibrillation by Amiodarone as a Predictor of Outcome After Pulmonary Vein Isolation. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70155

BibTeX
@article{Krnyk2026,
  author = {Krányák, Dóra and Novák, Adél and Pataky, Noémi and Sághy, László and Vámos, Máté and Szili-Török, Tamás and Pap, Róbert and Other Members of the Szeged Electrophysiology Study Group, Other Members of the Szeged Electrophysiology Study Group},
  title = {Utility of Pharmacologic Conversion of Persistent Atrial Fibrillation by Amiodarone as a Predictor of Outcome After Pulmonary Vein Isolation},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  doi = {10.1111/jce.70155}
}
Kostenlos starten →